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Abstract
Objectives: Evidence-based guidelines for the treatment of severe acute pancreatitis have been estab-
lished. This study was conducted to investigate the hypothesis that deviation from guidelines occurs
frequently.
Methods: With institutional review board approval, the outside medical records of patients with severe
pancreatitis who were transferred to the study institution during the period from July 2005 to May 2012
were reviewed. Severe pancreatitis was defined using the Atlanta Classification criteria. Records were
reviewed with respect to published guidelines defining the appropriate use of imaging, antibiotics and
nutritional support.
Results: A total of 538 patients with acute pancreatitis were identified. Of 67 patients with severe acute
pancreatitis, 44 (66%) were male. The mean age of the patients was 55 years. Forty-five of 61 (74%)
patients for whom relevant data were available were imaged upon admission, but only 15 (31%) patients
were imaged appropriately by computerized tomography with i.v. contrast to assess the presence of
necrosis or other complications. In patients for whom relevant data were available, prophylactic antibi-
otics were initiated in the absence of culture data or a specific infectious target in 26 (53%) patients. Total
parenteral nutrition (TPN) was administered to 38 (60%) of 63 patients for whom relevant data were
available; only 10 (17%) patients received enteric feeding. No nutritional support was provided to 15
(23%) patients.
Conclusions: Adherence to best practice guidelines in the treatment of severe pancreatitis is poor. The
consistent application of current knowledge might improve outcomes in these patients.
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Introduction
Acute pancreatitis leads to approximately 210 000 hospital admis-
sions each year in the USA. Fortunately, the majority of affected
patients will experience rapid resolution of their symptoms with
conservative treatment measures. However, a complicated clinical
course ensues in approximately 25% of patients. Although the
overall mortality rate in pancreatitis is only 5%, the presence of
pancreatic necrosis and multi-system organ failure are associated
with mortality rates of 17% and 47%, respectively.1 Thus, patients
destined to follow this severe clinical course must be identified
early so that their nutritional support, risk for infection and any
operative intervention can be managed appropriately.
To identify this subgroup of patients, a number of classification
systems (APACHE II, Ranson, Glasgow, Balthazar, Atlanta2) have
been developed based on objective clinical, biochemical and
radiographic criteria. The Balthazar Classification scheme is
image-based and utilizes contrast-enhanced computerized tom-
ography (CT) obtained at 48–72 h after the onset of symptoms.
Funding support: Cracchiolo Foundation.
*A. Vlada and B. Schmit contributed equally to this work.
This manuscript was presented at the annual AHPBA meeting, Miami,
20–24 February 2013.
DOI:10.1111/hpb.12140 HPB
HPB 2013, 15, 822–827 © 2013 International Hepato-Pancreato-Biliary Association
This timeframe optimizes the ability to identify the absence or
presence and extent of pancreatic necrosis. The extent of necrosis
strongly correlates to the risk for subsequent infectious complica-
tions and thus an index CT demonstrating necrosis is of consid-
erable clinical value.3 The Atlanta Classification system also
provides prognostic information and has been most widely uti-
lized for clinical research. This system utilizes objective clinical
data as inclusion criteria (Ranson score of >3 or APACHE II score
of >8) and defines severe acute pancreatitis (SAP) as being asso-
ciated with local and/or systemic complications.2 One limitation
of this system is that it actually identifies a diverse population of
patients,4–7 but a recently published revision5 now subdivides
this into patients with moderately severe5–7 and critically severe
categories of disease.8,9 The updated Atlanta Classification
achieves this additional level of stratification by differentiating
between local and systemic complications, their timing and dura-
tion.5 Together, these classification systems facilitate the identifi-
cation of at-risk patients and subsequent management decisions
on their need for critical care, nutritional support and surgical
intervention.
An extensive literature has identified the interventions that
provide the best outcomes for patients with SAP and represents
the basis of published, best practice treatment guidelines.1,10–15
These recommendations address the timing and modality of
imaging, the use of prophylactic antibiotics, and the introduction
and modality of nutritional support (Table 1). These data also
provide guidance for other interventions, including endoscopic
retrograde cholangiopancreatography (ERCP) percutaneous
drainage or other operative procedures, but these recommenda-
tions are not as broadly applicable. Poor adherence to these rec-
ommendations has been reported in the UK,Western Europe and
New Zealand,16–20 although recent audits suggest compliance has
been improving.21,22 Surprisingly, data from the USA are lacking.
Thus, adherence to best practice guidelines for the treatment of
SAP amongst physicians in the southeastern USA was assessed. It
was hypothesized that adherence to these guidelines is poor.
Materials and methods
Following institutional review board approval, medical records
were obtained for all patients admitted to the University of Florida
and Shands Teaching Hospital (UF & Shands) with the primary
diagnosis of acute pancreatitis [International Classification of
Diseases, 9th Revision (ICD-9) code 577.0] between July 2005 and
May 2012. Patients under the age of 18 years at the time of diag-
nosis and patients who were directly admitted to the study insti-
tution were excluded.
Patients without SAP were excluded. The designation of SAP
was based on the Atlanta Classification.2 Thus, any patient with
acute pancreatitis and either organ failure or local complications
was included. Organ failure was defined as any of the following:
shock [systolic blood pressure of <90 mmHg, pulmonary insuffi-
ciency indicated by an arterial blood oxygen pressure (PaO2) of
<60 mmHg as measured on room air or need for ventilator
support]; renal failure (creatinine of >2 mg/dl following rehydra-
tion or need for renal replacement therapy); disseminated intra-
vascular coagulation (platelet count of <100 000/ml and
fibrinogen of <1 g/l), andmetabolic disturbances (calcium level of
<7.5 mg/dl). Local complications included acute fluid collections,
pancreatic necrosis, pseudocyst formation and pancreatic abscess.
Patients presenting with a Ranson score of 3 calculated within
48 h of admission to the referring institution were also included.
Following the identification of patients with SAP transferred
from outside institutions, outside and institutional medical
records were retrospectively reviewed for each patient. Records
reviewed included admission and progress notes, radiology
reports, laboratory test values, procedural notes and nursing
notes. Patients for whom available records were inadequate to
assess at least two items of interest were excluded from further
review. The calculation of any given outcome measure was based
on data for only those patients whose records for that variable
were clear and complete. Thus, although the total number of
patients is 67, an outcome measure may refer to fewer than 67
patients because of incomplete transfer records. Actual treatment
patterns were compared with best practice standard guidelines
with respect to the use and timing of appropriate imaging
(contrast-enhanced CT), the use and spectrum of antibiotics,
and the timing of the initiation and the modality of nutritional
support.1
Results
Clinical characteristics of the patient population
Of 538 patients admitted with acute pancreatitis, 67 met the study
inclusion criteria. The clinical characteristics of the cohort are
summarized in Table 2. These patients were transferred from 38
different hospitals in Florida. The mean  standard deviation
(SD) length of stay at the referring institution prior to transfer was
13.7  12.4 days (range: 1–56 days; median: 11.0 days). 54% of
patients required intensive care for at least a portion of their stay
prior to transfer. The mean SD Ranson score at the time of the
initial hospital admission was 3.3 1.8 (range: 1–8; median: 3.0).
Following transfer, the median hospital stay was 29.0 days. Six
(9%) patients died following transfer.
Thirty-five (52%) patients had biliary pancreatitis (Table 3).
Alcohol abuse was the aetiology in 18% of cases. Post-ERCP pan-
Table 1 Summary of pertaining recommendations
Parameters Recommendationsa
Imaging Perform contrast-enhanced computed tomography
imaging 2–3 days after admission for the timely
identification of pancreatic necrosis
Antibiotics The use of prophylactic antibiotics is not
recommended
Nutrition For nutritional support, enteral nutrition should be
used instead of total parenteral nutrition
aAs outlined in Banks et al., 2006.1
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creatitis was present in three (4%) patients, hyperlipidaemia in
four (6%), pancreas divisum in one (1.5%) and pancreatic head
mass in one (1.5%). Two cases (3%) were likely to have been
induced by medications, and 10 (15%) had no clearly identifiable
cause.
Assessment of adherence to best practice guidelines
Forty-five of 61 (74%) patients with adequate documentation for
assessment underwent abdominal imaging upon admission
(within 24 h) (Table 4). Of these patients, 40 (66%) underwent
CT. Fifteen (25%) patients underwent their first radiological
imaging after the initial evaluation (>24 h). This occurred at an
average of 3.1 days (range: 1–7 days) post-admission. One indi-
vidual was not imaged at the referring institution and was trans-
ferred <48 h after admission. The initial mode of abdominal
imaging was a CTwith i.v. contrast in 72% of patients, CT without
contrast in 18%, and ultrasound examination alone in 8%. Of the
patients who stayed beyond 48 h at the referring hospital, 15
(31%) underwent a CT with i.v. contrast at 48–72 h. This sub-
group includes patients who underwent a repeat CT in addition to
CT at admission and patients who were not imaged by CT upon
admission.
A total of 51 patients (79%) received antibiotic treatment
during their pre-transfer stay; for 26 (53%) of these patients,
treatment was empiric and did not target a specific infection
source. Of the patients who were prescribed prophylactic treat-
ment, 11 (42%) received carbapenems and the remaining 15
(58%) patients were given other antibiotics. Seven patients
received imipenem or imipenem and cilastatin, and four patients
Table 2 Patient demographics
Parameters Value
Patients, n 67




Body mass index, kg/m2, mean (range) 30 (17–43)
Comorbidities, n (%)
Coronary artery disease 20 (30%)
Diabetes mellitus 20 (30%)
Hypertension 42 (63%)
COPD/active smoking 21 (31%)
Alcohol abuse 11 (16%)
Chronic renal insufficiency 4 (6%)
CVOD (TIA, stroke, CEA) 5 (8%)
Dyslipidaemia 22 (33%)
Ranson scorea, median (range) 3.0 (1–8)
LoS at referring institution, days, median (range) 11.0 (1–56)
Patients admitted to ICU at referring institution, n (%) 33 (54%)
LoS at UF & Shands Hospital, days, median (range) 29.0 (1–182)
aAs calculated based on parameters measured within the first 48 h of
admission at the referring institution.
COPD, chronic obstructive pulmonary disease; CVOD, cerebral vascular
occlusive disease; TIA, transient ischaemic attack; CEA, carotid endar-
terectomy; LoS, length of stay, UF & Shands, University of Florida and
Shands Teaching Hospital.
Table 3 Disease-specific detailsa
Parameter n (%)
Local complications
Necrotizing pancreatitis 31 (47%)
Infection 14 (21%)
Pseudocyst 23 (35%)
Multi-organ failure 24 (38%)
Procedures
Surgical 7 (11%)
Interventional radiology 18 (28%)
ERCP 8 (12%)
aDiagnoses and interventions as established or performed during the
patient's stay at the outside institution.
ERCP, endoscopic retrograde cholangiopancreatography.
Table 4 Practice guideline adherence details
Parameter Value
Modality of initial imaging, n (%)
CT with i.v. contrast 43 (72%)
CT without i.v. contrast 11 (18%)
Abdominal ultrasound 5 (8%)
No abdominal radiological imaging 1 (1.5%)
Timing of CT imaging, n (%)
At time of admissiona 40 (66%)
After admission 15 (25%)
Time from admission, days, mean (range) 3.1 (1–7)
CT with i.v. contrast at 48–72 h, n (%) 15 (31%)
Antibiotic use, n (%) 51 (79%)
Prophylactic useb 26 (53%)
Carbapenem antibiotics 11 (42%)
Non-carbapenem antibiotics 15 (58%)
Nutrition
Time without nutritionc, days, mean (range) 2.6 (0–7)
Enteral feeding, n (%) 10 (17%)
TPN administration, n (%) 38 (60%)
Enteral or oral feeding used or considered first,
n (%)
7 (23%)
Albumind, g/dl, mean (range) 2.6 (1.8–4.1)
aWithin first 24 h, as part of admission investigative process.
bAntibiotics initiated in the context of leukocytosis and/or fever, with no
specific infective process targeted.
cTime until commencement of either artificial nutrition or oral diet as
calculated from time of admission.
dAs measured upon admission to University of Florida and Shands
Teaching Hospital.
CT, computed tomography; TPN, total parenteral nutrition.
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were prescribed meropenem. For patients who did not receive
carbapenems, the most common prophylactic antibiotics were
vancomycin (n = 7), metronidazole (n = 7), levofloxacin (n = 5),
piperacillin-tazobactam (n = 4) and cefepime (n = 3).
Sixty of the 64 (94%) patients for whom adequate nutrition
records were available were fasted at the time of admission; four
(6%) were allowed to continue an oral diet. Patients were main-
tained without any nutritional support for a mean SD period of
2.6  2.1 days (range: 0–7 days). Ten (17%) patients received
enteral nutrition via a nasoenteric or percutaneous endoscopic
gastrostomy (PEG) tube, and 38 (60%) received total parenteral
nutrition (TPN). The latter was started at a mean of 3.8 days
(range 0–23 days), and enteral feeding was started at a mean of 2.0
days (range: 0–4 days). For the subset of patients who were nour-
ished parenterally, seven of 31 made an initial attempt to feed
orally or enterally. Causes for switching to TPN in these patients
included intolerance of oral diet (n = 4), inability to place a
nasoenteric feeding tube (n = 1) and intolerance of tube feeding
(n = 2). Fifteen (23%) patients did not receive any nutritional
support. The median stay at the outside institution in patients
who received no nutritional support was 3 days (range: 1–13
days). Mean SD albumin in the entire cohort was 2.6 0.6 g/dl
(range: 1.6–4.1 g/dl).
Upon transfer, 40 (60%) patients underwent a new CT with i.v.
contrast within 24 h of admission. Two (3%) patients underwent
CT without i.v. contrast on the basis of renal impairment, and 25
(37%) patients were deemed to have had adequate recent imaging
performed at the outside institution. Of the 26 patients who
received prophylactic antibiotics at the outside institution, 25 were
still being treated upon transfer to the study hospital.Within 48 h
of arrival, antibiotics were discontinued in seven of these patients,
therapy was continued on a prophylactic basis in eight patients,
and antibiotic therapy was continued in order to appropriately
treat a culture-proven infection in 10 patients. Of the 38 patients
who arrived on TPN, 29 were converted to enteral nutrition,
eight were continued on TPN, and one patient died shortly after
transfer.
Discussion
The present study found that, in general, the treatment of patients
with SAP prior to transfer failed to adhere to evidence-based best
practice guidelines. Computed tomography imaging was inappro-
priately utilized with respect to timing and the use of i.v. contrast.
Prophylactic antibiotic usage was widespread but infrequently
included a carbepenem. Nutritional support was initiated in a
timely fashion; however, most patients received TPN and few
received enteral nutrition.
Best practice guidelines for the treatment of patients with
severe pancreatitis were published by Banks et al.1 in 2006, and
were based on evidence published prior to the start of the period
covered in the present study (in 2005). These guidelines recom-
mend imaging with contrast-enhanced CT at 48–72 h post-
admission to delineate local complications and the presence and
extent of necrosis. This time interval has been identified as the
optimum period in which to detect the complication of pancreatic
necrosis.3,5 Morphological findings on CT at the time of admis-
sion were found to have poor predictive value and thus its use as
a triage tool is not recommended.23 A large proportion of patients
in the present study (66%) underwent CT within 24 h of admis-
sion, but only 31% of patients were imaged with contrast-
enhanced CT at 48–72 h. Thus, although CT as part of the initial
diagnostic evaluation of severe abdominal pain may be appropri-
ate, the majority of these patients did not benefit from the prop-
erly timed imaging essential to treat them appropriately.
The occurrence of infection in the pancreatic field sharply
increases mortality,1 and the revised Atlanta Classification
acknowledges that mortality increases further in the presence of
persistent organ failure.5 The use of prophylactic antibiotics in
severe pancreatitis is controversial and this controversy persisted
during the period of this study.24–28 Some studies have shown
evidence supporting the use of prophylactic imipenem in severe
pancreatitis,24,29,30 whereas others have found no benefit.31,32 A 2010
meta-analysis by Villatoro et al. found a statistically significant
improvement in the rate of pancreatic infections following treat-
ment with imipenem, but no difference in mortality.33 This runs
counter to the findings of Wittau et al., who specifically analysed
carbapenem prophylaxis in a separate meta-analysis and found no
benefit.34 This difference in findings can be attributed in part to the
fact that two additional trials that failed to show added benefit with
prophylactic imipenem treatment31,32 were included in the study by
Wittau et al.34 The most recent meta-analysis on the subject, by
Wittau et al., found no reduction in mortality pancreatic and
non-pancreatic infections with the use of antibiotic prophylaxis.34
Given that this practice is associated with an increased risk for
pancreatic fungal infections35–37 and increased antibiotic resist-
ance,38 it has been further discouraged. The present study found
that a large proportion of the patient population (53%) had been
prescribed antibiotics for the clinical features of a systemic inflam-
matory response in the absence of a specifically targeted infective
source.Although itmight be useful to apply the benefit of doubt for
the use of imipenem, given the ongoing debate regarding its pro-
phylactic benefit,more than half of the present cohort (58%) were
given non-carbapenem antibiotics.
Nutritional support is an important component of the man-
agement of SAP. Multiple randomized trials have demonstrated
that enteral feeding is associated with better outcomes than
TPN.1,39–41 A recent meta-analysis has shown statistically signifi-
cant decreases in risk for infectious complications and mortality
with the use of enteral rather than parenteral feeding.40 Despite
this, the use of TPN remains pervasive in both the present study
population and in the previously published literature.21,42 In the
present series, the mean time of commencement of nutritional
supplementation was day 2.0 for enteral feeding and day 3.8 for
TPN. This is in concurrence with recommendations that nutri-
tional supplementation be started early in the disease process.1
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However, recent evidence suggests that if parenteral nutrition
must be used, it should not be administered until day 5 because
the early employment of TPN (within 48 h) has been associated
with worse outcomes.43 Twelve of the 38 patients who received
TPN in the present study were set on this route by day 3 of their
hospital stay.
The present findings are similar to those reported in a number
of publications from outside the USA. One recent practitioner
questionnaire-based study by Rebours et al. looked at similar vari-
ables in France.21 These investigators found suboptimal adherence
to SAP treatment guidelines across a large number of public and
private institutions surveyed in 2008, although their findings indi-
cated an improvement in compliance compared with a previous
survey conducted in 2001.21 Specifically, the use of prophylactic
antibiotics was found to be low at 8%,21 which is much lower than
the rate of 53% observed in the present study. Similarly, CTs were
performed at the time of admission in 28% of patients and at 48 h
in 69%, whereas the present study found rates of 66% and 31%,
respectively, at these time-points. Rebours et al. 21 reported that
parenteral nutrition was employed in 42% of patients, whereas
enteral nutrition was used in 58%. A 2007 prospective observa-
tional study assessing compliance in Italian centres found
parenteral nutrition was administered in 89% of patients, whereas
enteral nutrition was applied in only 5%.19 This highlights the
heterogeneity of practice patterns across the world. Thus, failure
to adhere to best practice guidelines is not unique to the US health
system.
The present study has a number of limitations. It is retrospec-
tive in nature and was compelled to exclude a significant number
of patients because adequate documentation was lacking. In addi-
tion, it should be acknowledged that charted notes often do not
effectively communicate clinical thought processes. Another limi-
tation concerns the fact that the present study assessed care pro-
vided at only community hospitals in Florida. It is very possible
that clinical practice patterns differ at large academic centres and
elsewhere in the USA. Thus, the present findings should not be
considered as representative of treatment patterns at state or
national levels.
Failure to apply best practice guidelines is not unique to the
context of severe pancreatitis and remains an unresolved chal-
lenge. Nonetheless, opportunities for improvement in the knowl-
edge of and adherence to these guidelines certainly exist.
Assuming culpability for the present data, the current authors
have begun a regional outreach effort to improve the knowledge of
emergency department and intensive care unit physicians of the
identification of severe pancreatitis and optimum subsequent
treatment. Subspecialty organizations, such as the Americas
Hepato-Pancreato-Biliary Association (AHPBA) and other socie-
ties, could develop continuing medical education resources and
other outreach strategies targeting community-based physicians.
Perhaps this might include contributions to widely disseminated
publications. Outwith physician influence, compliance with these
guidelines might be tied to reimbursement, as has applied with
other best practices through the Centers for Medicare and Med-
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